Paholo Barboglio Romo

Paholo Barboglio Romo

Auto-generated profile, based on publicly available information

Paholo Barboglio Romo

Department of Urology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Journal of Urology
Verified
Journal Article
Closed access
GLGiulia Lane
Giulia Lane
AGAlyssa Gracely
Alyssa Gracely
CBChristine Bassis
Christine Bassis
SGStephen E. Greiman
Stephen E. Greiman
PRPaholo Barboglio Romo
Paholo Barboglio Romo
ACAnne P. Cameron
Anne P. Cameron
Purpose:We aimed to characterize the urinary microbiome of catheterizing patients with neurogenic lower urinary tract dysfunction (NLUTD) and to evaluate differences based on type of bladder manage...

1 November 2025 in Journal of Urology
Verified
Journal Article
Closed access
GIGiulia M. Ippolito
Giulia M. Ippolito
ICIrene Crescenze
Irene Crescenze
HSHannah Sitto
Hannah Sitto
RPRita R. Palanjian
Rita R. Palanjian
DRDaniel Raza
Daniel Raza
PGPriyanka Gupta
Priyanka Gupta
We assessed the effects of vaginal lasers for treating stress urinary incontinence (SUI) in women. This systematic review and meta-analysis included randomized trials of women with SUI and assessed therapy with vaginal laser vs sham, control, or topical treatments. Nine studies of 689 women with SUI were included. Overall, the data regarding vaginal laser vs sham treatments were uncertain, and few studies assessed outcome beyond 1 year. In the short term, there may be no difference between the number of continent women between women who underwent vaginal laser compared with sham (risk ratio, 1.50; 95% CI, 0.72-3.10; I2 = 81%; n = 196; very low-certainty evidence). Although vaginal lasers may improve patient-reported incontinence measures compared with sham, the point estimate for improvement does not meet the prespecified minimally clinical importance differences (mean difference, -1.42 points; 95% CI, -2.41 to -0.43; I2 = 54%; n = 632; very low-certainty evidence). Only 1 study provided evidence comparing vaginal laser with topical estrogen. There were no major adverse events in any treatment group at any time point. Vaginal lasers may have little to no effect on SUI as measured by both clinical assessment in the short term compared with sham, control, or topical treatments, but the evidence is uncertain. Vaginal lasers may improve patient-reported measures of SUI, but the evidence is uncertain, and the change may not be noticeable to patients. No major adverse events were reported.

10 August 2026 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
AHAva Harb
Ava Harb
PBPiroz Bahar
Piroz Bahar
SDStephanie Daignault-Newton
Stephanie Daignault-Newton
CSCaitlin Seibel
Caitlin Seibel
PRPaholo Barboglio Romo
Paholo Barboglio Romo
YZYu Zheng
Yu Zheng

29 October 2026 in Neurourology and Urodynamics
Verified
Journal Article
Open access
PDF file
ZSZhina Sadeghi
Zhina Sadeghi
EBEmma C. Bethel
Emma C. Bethel
SDStephanie Daignault-Newton
Stephanie Daignault-Newton
GIGiulia M. Ippolito
Giulia M. Ippolito
ARAdriana Rush
Adriana Rush
JSJohn T. Stoffel
John T. Stoffel
Introduction: We investigated demographic, diagnostic, and socioeconomic variables associated with continuation and discontinuation of onabotulinum toxin (BTX) therapy in adult patients treated for idiopathic and neurogenic urgency urinary incontinence (UUI). Methods: Patients who initiated BTX for UUI between 2015 and 2018 at a tertiary academic referral center were identified from CPT codes and followed through 2020 ( n = 723). The cohort was divided into patients who continued BTX therapy (received ≥1 BTX treatment within 2 years of initial injection) (Group A), and patients who stopped BTX (received no additional BTX for at least 2 years after the last injection) (Group B). Demographic variables were extracted using chart review and administrative data. Socioeconomic differences were estimated using affluence index (AI) and disadvantage index (DI) from their last botox injection, calculated using U.S. census tract indicators. AI factors include household income, professions of household members, and educational background. DI factors include neighborhood proportion of female‐headed households, receiving public assistance or not, household income level, and level of employment. Indexes ranged from 0.0 (least affluent or disadvantaged) to 1.0 (most affluent or advantaged). Results: The mean cohort age ( n = 723) was 57% and 69% were female. After the initial injection, 40% received additional injections within 2 years (Group A) and 60% did not (Group B). There were no demographic differences between groups. Univariate comparison of affluence and disadvantage indexes revealed Group A affluence was not significantly different (AI = 0.38 vs 0.37, p = 0.2) but was slightly less disadvantaged (DI = 0.072, vs. 0.081; p = 0.036) than Group B. Multivariable analysis including demographic and socioeconomic factors demonstrated that higher affluence index was associated with lower odds of BTX discontinuation (OR = 0.90 per 0.1‐unit increase, 95% CI: 0.82–0.99, p = 0.029), while there was insufficient evidence of an association between disadvantage index and discontinuation (OR = 1.23 per 0.1‐unit increase, 95% CI: 0.99–1.54, p = 0.06). After adding neurogenic versus non‐neurogenic etiology of UUI, the socioeconomic associations were no longer significant. Patients with a non‐neurogenic diagnosis had significantly greater odds of BTX discontinuation than patients with a neurogenic diagnosis (OR = 1.97, 95% CI: 1.35–2.89, p < 0.001). Conclusion: Approximately 40% of patients continued BTX treatment for UUI beyond the initial injection period. Neurogenic diagnosis was strongly associated with treatment persistence, with non‐neurogenic patients demonstrating greater odds of discontinuation. Socioeconomic factors were not independently associated with discontinuation after adjustment for clinical diagnosis. Clinical Trial Registration: This is a retrospective study with IRB approval. This study is not a clinical trial and will not be registered as a clinical trial.